Renal cell carcinomas (RCC) are emerging as a complex set of diseases that are having a
major socioeconomic impact and showing a continued rise in incidence throughout the …

Systemic treatment of renal cell carcinoma has changed dramatically since 2007, with the
development and approval of six new agents, which target complex molecular pathways …

Background Gene expression signatures have proven to be useful tools in many cancers to
identify distinct subtypes of disease based on molecular features that drive pathogenesis …

Purpose Pazopanib, an oral angiogenesis inhibitor, is approved for the treatment of
advanced renal cell carcinoma (RCC). Response to pazopanib monotherapy varies …

Background: We evaluated germline single nucleotide polymorphisms (SNPs) for
association with overall survival (OS) in pazopanib-or sunitinib-treated patients with …

Despite recent advances, metastatic renal cell carcinoma remains largely an incurable
disease. Vascular endothelial growth factor and mammalian target of rapamycin inhibitors …

Before the advent of molecular targeted therapy, treatment of metastatic renal cell carcinoma
(mRCC) involved immunotherapy with high-dose interleukin (IL)-2 in selected patients …

Abstract With the Food and Drug Administration approval of 6 novel targeted agents since
December 2005 and limited comparative trials to discern relative efficacy, the treatment of …

Within the past 5 years, the United States Food and Drug Administration have approved six
targeted agents for the treatment of metastatic renal cell carcinoma (mRCC). While this offers …

Renal cell carcinoma (RCC) is a heterogeneous disease. A rigorous diagnostic assessment
by a pathologist with close communication with the clinician provides more accurate …